Table 4.
Pooled Risk Ratios for Primary Prevention with Aspirin in People with Diabetes from Other Systematic Reviews
| Lead Author, Publication Year | All Cause Mortality | Cardiovascular Mortality | Myocardial Infarction | Stroke | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | RR (95% CI) | I2 | n | RR (95% CI) | I2 | n | RR (95% CI) | I2 | n | RR (95% CI) | I2 | |
| De Berardis, 2009 17 | 4 | 0.93 (0.82–1.05) | 0% | 4 | 0.94 (0.72–1.23) | 57% | 6 | 0.86 (0.61–1.21) | 62% | 5 | 0.83 (0.72–1.23) | 53% |
| ATT Collaboration, 2009 18 | NR | NR | 6 | 0.88 (0.67–1.15)* | NR | NR | 0.81 (0.51–1.30)† | NR | ||||
| Zhang, 2010 19 | 5 | 0.95 (0.85–1.06) | 0% | 5 | 0.95 (0.71–1.27) | 41% | 7 | 0.85 (0.65–1.11) | 55% | 6 | 0.83 (0.63–1.10) | 44% |
| Pignone, 2010 16 | NR | NR | 9 | 0.91 (0.79–1.05)‡ | 8% | 9 | 0.85 (0.66–1.11) | 36% | ||||
| Younis, 2010 20 | 3 | 0.96 (0.78–1.18) | NR | NR | 6 | 0.95 (0.76–1.18) | NR | 3 | 0.75 (0.55–1.02) | NR | ||
| Stavrakis, 2011 21 | 4 | 0.99 (0.82–1.20) | 0% | 4 | 0.99 (0.62–1.60) | 39% | 3 | 0.83 (0.40–1.72) | 64% | 3 | 0.70 (0.44–1.11) | 29% |
| Simpson | 7 | 1.01 (0.85–1.19) | 0% | 7 | 0.98 (0.63–1.53) | 26% | 9 | 1.06 (0.75–1.51) | 70% | 10 | 0.98 (0.71–1.35) | 46% |
*Reported as “Serious Vascular Events”
†Reported as “Ischemic Stroke”
‡Combined “Major Coronary Event (coronary heart disease death + nonfatal myocardial infarction + sudden death)” reported in three studies with “Coronary heart disease death + nonfatal myocardial infarction” reported in one study and “Fatal + non-fatal myocardial infarction” reported in five studies
n=Number of studies contributing data; ATT = Antithrombotic Trialists’; NR = Not Reported; RR = Pooled Risk Ratio; 95% CI = 95% Confidence Interval